Who makes 5cc Vivigen and local autograft?

5cc Vivigen and local autograft is developed by Virtua Health, Inc..

What development phase is 5cc Vivigen and local autograft in?

5cc Vivigen and local autograft is FDA-approved (marketed).

Last reviewed 2026-05-15 · How we verify

5cc Vivigen and local autograft

Virtua Health, Inc. · FDA-approved active Biologic Quality 0/100

5cc Vivigen and local autograft, marketed by Virtua Health, Inc., holds a niche position in the therapeutic landscape with its unique combination therapy approach. The key composition patent, expiring in 2028, provides a significant barrier to entry for potential generic competitors. However, the lack of detailed revenue data and primary trial results poses a risk in assessing the drug's market performance and clinical efficacy.

At a glance

Generic name	5cc Vivigen and local autograft
Sponsor	Virtua Health, Inc.
Modality	Biologic
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

rhBMP-2 Versus Vivigen in Lumbar Fusion Procedures (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

5cc Vivigen and local autograft CI brief — competitive landscape report
5cc Vivigen and local autograft updates RSS · CI watch RSS
Virtua Health, Inc. portfolio CI